<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01338909</url>
  </required_header>
  <id_info>
    <org_study_id>PATRASCARDIOLOGY-4</org_study_id>
    <nct_id>NCT01338909</nct_id>
  </id_info>
  <brief_title>Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI)</brief_title>
  <acronym>PRO-GR-4</acronym>
  <official_title>Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)and Presenting With High Platelet Reactivity, as Assessed With a Point of Care Assay, After 600mg Clopidogrel Loading Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Patras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Patras</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, randomized, single-blind, investigator-initiated, pharmacological&#xD;
      study with a parallel design. Patients with ST elevation myocardial infarction undergoing&#xD;
      primary percutaneous coronary intervention and presenting high platelet reactivity as&#xD;
      assessed with the Verify Now P2Y12 assay-Accumetrics(Platelet Reactivity Units -PRU≥235) at 2&#xD;
      hours post-clopidogrel 600mg LD (Day 0), as assessed with the Verify Now P2Y12 assay, will be&#xD;
      randomized after informed consent, in a 1:1 ratio to the following treatment groups:&#xD;
&#xD;
      Group Α: Clopidogrel 150mg per day,starting from Day 1 until Day 5 (5 days after&#xD;
      randomization) Group Β: Prasugrel 60 mg immediate loading (on Day 0) followed by 10mg/day&#xD;
      starting from Day 1 until Day 5 (5 days after randomization).&#xD;
&#xD;
      Platelet reactivity assessment will be performed 2 hours after randomization (Day 0), 24 h&#xD;
      after randomization (Day 1) and on Day 5. Documentation of major adverse cardiac events&#xD;
      (death, myocardial infarction, stroke, revascularization procedure with PCI or CABG)and&#xD;
      serious adverse events (bleeding, other adverse events)will be performed until Day 5.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>24 hours post randomization (Day 1)</time_frame>
    <description>Platelet Reactivity assessed by VerifyNow P2Y12 assay 24 hours post randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>2 hours post randomization (Day 0)</time_frame>
    <description>Platelet Reactivity assessed by VerifyNow P2Y12 assay 2 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet reactivity</measure>
    <time_frame>5 days post randomization (Day 5)</time_frame>
    <description>Platelet reactivity assessed by VerifyNow P2Y12 assay 5 days post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyporesponsiveness rate</measure>
    <time_frame>2 hours post randomization (Day 0)</time_frame>
    <description>Hyporesponsiveness rate (PRU≥235 assessed with the VerifyNow P2Y12 assay)2 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyporesponsiveness rate</measure>
    <time_frame>24 hours post randomization (Day 1)</time_frame>
    <description>Hyporesponsiveness rate (PRU≥235 assessed with the VerifyNow P2Y12 assay)24 hours post randomization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyporesponsiveness rate</measure>
    <time_frame>5 days post randomization (Day 5)</time_frame>
    <description>Hyporesponsiveness rate (PRU≥235 assessed with the VerifyNow P2Y12 assay)5 Days post randomization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel 150mg/day starting from Day 1 until Day 5</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5</description>
    <arm_group_label>Prasugrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Clopidogrel 150mg/d starting from Day 1</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years old&#xD;
&#xD;
          2. Patients with STEMI undergoing primary PCI with stenting&#xD;
&#xD;
          3. Platelet reactivity in PRU ≥235 2 hours post 600 mg clopidogrel loading dose&#xD;
&#xD;
          4. Informed consent obtained in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Treatment with other investigational agents (including placebo) or devices within 30&#xD;
             days prior to randomization or planned use of investigational agents or devices prior&#xD;
             to the Day 5.&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Breastfeeding&#xD;
&#xD;
          4. Inability to give informed consent or high likelihood of being unavailable until Day&#xD;
             5.&#xD;
&#xD;
          5. Cardiogenic shock&#xD;
&#xD;
          6. Major periprocedural complications (death, stent thrombosis, vessel perforation,&#xD;
             arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous&#xD;
             antiarrhythmic agents, respiratory failure requiring intubation, vascular injury&#xD;
             (pseudoaneurysm, arteriovenous shunt, retroperitoneal bleeding or hematoma &gt;5 cm at&#xD;
             the arterial catheter insertion site), major bleeding (need for bood transfusion or&#xD;
             drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).&#xD;
&#xD;
          7. Unsuccessful PCI (residual stenosis &gt; 30% or flow &lt; ΤΙΜΙ 3) or planned staged PCI in&#xD;
             the next 5 days after randomization&#xD;
&#xD;
          8. Requirement for oral anticoagulant prior to the Day 5&#xD;
&#xD;
          9. Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.&#xD;
&#xD;
         10. Known hypersensitivity to prasugrel or ticagrelor&#xD;
&#xD;
         11. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal&#xD;
             bleeding within the previous 6 months.&#xD;
&#xD;
         12. Other bleeding diathesis, or considered by investigator to be at high risk for&#xD;
             bleeding on thienopyridine therapy.&#xD;
&#xD;
         13. Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm,&#xD;
             arteriovenous malformation, aneurysm).&#xD;
&#xD;
         14. Thrombocytopenia (&lt;100.000 / μL) at randomization&#xD;
&#xD;
         15. Anaemia (Hct &lt;30%) at randomization&#xD;
&#xD;
         16. Polycythaemia (Hct &gt; 52%) at randomization&#xD;
&#xD;
         17. Periprocedural IIb/IIIa inhibitors administration&#xD;
&#xD;
         18. Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin&#xD;
             that cannot be adequately premedicated.&#xD;
&#xD;
         19. Recent (&lt; 6 weeks) major surgery or trauma, including GABG.&#xD;
&#xD;
         20. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
             or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of&#xD;
             the study.&#xD;
&#xD;
         21. INR&gt;1.5 at randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Patras University Hospital</name>
      <address>
        <city>Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Patras</investigator_affiliation>
    <investigator_full_name>Dimitrios Alexopoulos</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prasugrel</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>primary percutaneous coronary intervention</keyword>
  <keyword>high platelet reactivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

